Business Context and Reporting Period
This Form 8-K Current Report was filed by Nexalin Technology, Inc. (NXL) on August 28, 2026. The report discloses a material event regarding the departure of a senior executive. The company is incorporated in Delaware and trades on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and separation terms.
Material Changes
The primary material change reported is the departure of Carolyn Shelton from her role as Senior Vice President of Quality, Regulatory, and Clinical Affairs, effective August 28, 2026.
Management Commentary and Separation Terms
In connection with Ms. Shelton's departure, the Company entered into a separation agreement with the following terms:
- Base Salary: One month of continued base salary.
- Bonus: A 2026 bonus of $20,000.
- Equity: Accelerated vesting of unvested stock options and up to two years to exercise vested options.
- Benefits: Continued subsidy of health insurance premiums through September 30, 2026.
- Conditions: Ms. Shelton agreed to a release of claims, along with standard confidentiality, non-disparagement, and cooperation provisions.
The full text of the separation agreement will be filed as an exhibit to the Company's next periodic report.
Investor Verification Checklist
- Verify the impact of the departure on the Company's Quality, Regulatory, and Clinical Affairs operations.
- Review the upcoming periodic report for the full text of the separation agreement.
- Monitor for any subsequent announcements regarding the appointment of a replacement for the Senior Vice President role.
- Confirm if the accelerated vesting of stock options triggers any immediate dilution or accounting charges not detailed in this summary.